Table 1.
Baseline demographic and clinical characteristics, cardiovascular risk factors and treatments received.
| Variables |
n = 200 Median (IQR) or n (%) |
|---|---|
| Male, n (%) | 119 (59.5) |
| Age, years | 47.5 (40.0–56.0) |
| BMI, kg/m2 | 25.2 (23.1–28.6) |
| Disease duration, years | 4.3 (1.8–7.9) |
| Diabetes, n (%) | 45 (22.5) |
| Hypertension, n (%) | 68 (34.0) |
| CRP, mg/l | 4.9 (1.7–12.6) |
| ESR, mm/h | 21 (10.0–38.0) |
| Total cholesterol, mmol/l | 4.9 (4.2–5.6) |
| HDL, mmol/l | 1.3 (1.1–1.6) |
| LDL, mmol/l | 2.9 (2.3–3.4) |
| Triglycerides, mmol/l | 1.2 (0.9–1.8) |
| Glucose, mmol/l | 5.1 (4.8–5.6) |
| Systolic blood pressure, mmHg | 125 (115–140) |
| Diastolic blood pressure, mmHg | 78 (70–85) |
| Ever smoker, n (%) | 59 (34.9) |
| Ever drinker, n (%) | 50 (33.6) |
| FRS | 8.4 (4.0–17.0) |
| Current treatment | |
| Lipid-lowering drugs, n (%) | 30 (15.0) |
| MTX, n (%) | 99 (49.5) |
| bDMARDs, n (%) | 17 (8.5) |
| NSAIDs, n (%) | 139 (69.2) |
| Steroid, n (%) | 2 (1.0) |
bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FRS, Framingham risk score; HDL, high-density lipoprotein cholesterol; IQR, interquartile range; LDL, low-density lipoprotein cholesterol; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drug.